When: Thursday, November 12th – from 6:00pm to 8:00PM
Where: CIC Boston, Meridian room, 5th floor, 50 Milk Street, Boston, MA 02109
Presentation in french, followed by a networking reception
Alexandre Detappe, 26 years old, is a medical radio-physicist. Currently in his second year of his thesis in co-supervision between the Doctoral School of Chemistry in Lyon and Harvard Medical School, he has decided to join the laboratory of Radiation Oncology of the Dana-Farber Cancer Institute/ Brigham and Women’s Hospital of Boston with the goal of perfecting his knowledge of nano-medicine.
Alexandre works in collaboration with the French company Nano-H, based in Lyon, that specializes in the design of nano-particles. For the past 10 years, Nano-H has developed an innovative nano-particle called AGuIX® that improves image guided radiotherapy for the treatment of cancer, from a diagnostic and therapeutic point of view, and the first clinical trial is planned for the beginning of 2016.
Passionate in nanotechnologies, Alexandre is responsible for carrying out a preclinical proof-of-concept with the nano-particles AGuIX® during the three years of his thesis, that will be finalized by the creation of a clinical trial at DFCI/BWH at the end of 2016. His research is essentially centered on the treatment of pancreatic cancer, a low survival rate cancer.
His presentation will detail the interest of using nano-particles in radiotherapy for the treatment of cancer, and particularly how nano-particles AGuIX® will permit the improvement of observed results with actual treatments.